Drug Profile
R 7025
Alternative Names: Maxy-alpha; R7025; RO 5014583Latest Information Update: 28 Nov 2007
Price :
$50
*
At a glance
- Originator Maxygen
- Class Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 26 Nov 2007 Discontinued - Phase-I for Hepatitis B treatment in New Zealand (SC)
- 26 Nov 2007 Discontinued - Phase-I for Hepatitis C treatment in New Zealand (SC)
- 06 Nov 2007 Final pharmacodynamics, adverse event and pharmacokinetics data from a phase I trial in healthy volunteers presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007)